Biocon: In US, we are now competing with Big Pharma – Times of India
BENGALURU: The decision by the US FDA to label Biocon’s insulin glargine as an interchangeable biosimilar is a momentous decision...
mazumdar-shaw
BENGALURU: The decision by the US FDA to label Biocon’s insulin glargine as an interchangeable biosimilar is a momentous decision...
